Literature DB >> 29468343

Authors' reply to Gandjour: "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany".

Alexander Kuhlmann1, J-Matthias Graf von der Schulenburg2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29468343     DOI： 10.1007/s10198-018-0956-4

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN： 1618-7598


× No keyword cloud information.
  13 in total

1.  Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.

Authors:  Alexander Kuhlmann; J-Matthias Graf von der Schulenburg
Journal:  Eur J Health Econ       Date:  2016-02-23

2.  Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.

Authors:  Louis P Garrison; Edward C Mansley; Thomas A Abbott; Brian W Bresnahan; Joel W Hay; James Smeeding
Journal:  Value Health       Date:  2009-10-23       Impact factor: 5.725

3.  Comment on "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany".

Authors:  Afschin Gandjour
Journal:  Eur J Health Econ       Date:  2018-02-06

4.  Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.

Authors:  Mark H Rozenbaum; Elisabeth A M Sanders; Albert Jan van Hoek; Angelique G S C Jansen; Arie van der Ende; Germie van den Dobbelsteen; Gerwin D Rodenburg; Eelko Hak; Maarten J Postma
Journal:  BMJ       Date:  2010-06-02

5.  Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.

Authors:  Arto A Palmu; Jukka Jokinen; Dorota Borys; Heta Nieminen; Esa Ruokokoski; Lotta Siira; Taneli Puumalainen; Patricia Lommel; Marjan Hezareh; Marta Moreira; Lode Schuerman; Terhi M Kilpi
Journal:  Lancet       Date:  2012-11-16       Impact factor: 79.321

6.  Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

Authors:  A Melegaro; W J Edmunds
Journal:  Vaccine       Date:  2004-10-22       Impact factor: 3.641

7.  Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.

Authors:  Roman Prymula; Pascal Peeters; Viktor Chrobok; Pavla Kriz; Elena Novakova; Eva Kaliskova; Igor Kohl; Patricia Lommel; Jan Poolman; Jean-Paul Prieels; Lode Schuerman
Journal:  Lancet       Date:  2006-03-04       Impact factor: 79.321

8.  Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.

Authors:  Steven B Black; Henry R Shinefield; Stella Ling; John Hansen; Bruce Fireman; David Spring; Jack Noyes; Edwin Lewis; Paula Ray; Janelle Lee; Jill Hackell
Journal:  Pediatr Infect Dis J       Date:  2002-09       Impact factor: 2.129

9.  Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands.

Authors:  Marie-Josée J Mangen; Mark H Rozenbaum; Susanne M Huijts; Cornelis H van Werkhoven; Douwe F Postma; Mark Atwood; Anna M M van Deursen; Arie van der Ende; Diederick E Grobbee; Elisabeth A M Sanders; Reiko Sato; Theo J M Verheij; Conrad E Vissink; Marc J M Bonten; G Ardine de Wit
Journal:  Eur Respir J       Date:  2015-07-09       Impact factor: 16.671

10.  The impact of community-acquired pneumonia on the health-related quality-of-life in elderly.

Authors:  Marie-Josée J Mangen; Susanne M Huijts; Marc J M Bonten; G Ardine de Wit
Journal:  BMC Infect Dis       Date:  2017-03-14       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.